{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:53:27Z","timestamp":1792439607603,"version":"4.5.0"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100020884","name":"Agencia Nacional de Investigaci\u00f3n y Desarrollo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ymthe.2026.09.036","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:16:04Z","timestamp":1790810164000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Receptor-ligand matching for precision allogeneic NK cell cancer therapies"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3370-4878","authenticated-orcid":false,"given":"Pablo","family":"Castro-C\u00f3rdova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidora P.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Tapia-Rybertt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Jerez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maroun","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.09.036_bib1","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.09.036_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.09.036_bib3","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/S0140-6736(25)01671-X","article-title":"Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China","volume":"406","author":"Gao","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.09.036_bib4","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/bloodadvances.2020002701","article-title":"Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AML","volume":"5","author":"Shaffer","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2026.09.036_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1454427","article-title":"Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis","volume":"15","author":"Park","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303605","article-title":"NK cell exhaustion in the tumor microenvironment","volume":"14","author":"Jia","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib7","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/319675a0","article-title":"Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy","volume":"319","author":"K\u00e4rre","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.09.036_bib8","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/imm.12684","article-title":"Deciphering the killer-cell immunoglobulin-like receptor system at super-resolution for natural killer and T-cell biology","volume":"150","author":"B\u00e9ziat","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2026.09.036_bib9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/(SICI)1521-4141(199801)28:01<264::AID-IMMU264>3.0.CO;2-O","article-title":"Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases","volume":"28","author":"Le Dr\u00e9an","year":"1998","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/icb.2010.78","article-title":"Activating and inhibitory receptors of natural killer cells","volume":"89","author":"Pegram","year":"2011","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib11","first-page":"235","article-title":"Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells","volume":"49","author":"Thompson","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2026.09.036_bib12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1600-065X.2008.00660.x","article-title":"Negative signaling by inhibitory receptors: the NK cell paradigm","volume":"224","author":"Long","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2026.09.036_bib13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0167-5699(00)01745-X","article-title":"The ITAM-bearing transmembrane adaptor DAP12 in lymphoid and myeloid cell function","volume":"21","author":"Lanier","year":"2000","journal-title":"Immunol. Today"},{"key":"10.1016\/j.ymthe.2026.09.036_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101709","article-title":"FcRgamma Gene Editing Reprograms Conventional NK Cells to Display Key Features of Adaptive Human NK Cells","volume":"23","author":"Liu","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.ymthe.2026.09.036_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.898745","article-title":"Role of the ITAM-Bearing Receptors Expressed by Natural Killer Cells in Cancer","volume":"13","author":"Medjouel Khlifi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib16","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1182\/blood-2005-08-3504","article-title":"Multiplicity and plasticity of natural killer cell signaling pathways","volume":"107","author":"Chiesa","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.09.036_bib17","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","article-title":"The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy","volume":"8","author":"Paul","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib18","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1038\/ncomms6108","article-title":"SHP-1-mediated inhibitory signals promote responsiveness and anti-tumour functions of natural killer cells","volume":"5","author":"Viant","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.09.036_bib19","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.4049\/jimmunol.172.12.7385","article-title":"KIR2DL5 can inhibit human NK cell activation via recruitment of Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2)","volume":"172","author":"Yusa","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0952-7915(99)80048-X","article-title":"Natural killer cell activation and inhibition by receptors for MHC class I","volume":"11","author":"L\u00f3pez-Botet","year":"1999","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib21","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2004-08-3156","article-title":"A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules","volume":"105","author":"Fernandez","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.09.036_bib22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri3370","article-title":"Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution","volume":"13","author":"Parham","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.immuni.2006.06.013","article-title":"Human NK cell education by inhibitory receptors for MHC class I","volume":"25","author":"Anfossi","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.09.036_bib24","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/j.seminhematol.2020.10.005","article-title":"Selection of allogeneic hematopoietic cell transplant donors to optimize natural killer cell alloreactivity","volume":"57","author":"Shaffer","year":"2020","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib25","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1084\/jem.190.10.1505","article-title":"Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells","volume":"190","author":"Pende","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.09.036_bib26","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1084\/jem.186.7.1129","article-title":"p46, a novel natural killer cell-specific surface molecule that mediates cell activation","volume":"186","author":"Sivori","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.09.036_bib27","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/ni858","article-title":"Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D","volume":"3","author":"Diefenbach","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ni929","article-title":"NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway","volume":"4","author":"Billadeau","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib29","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","article-title":"The phosphoinositide 3-kinase pathway","volume":"296","author":"Cantley","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.09.036_bib30","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1038\/s41467-018-07277-9","article-title":"Crosstalks between mTORC1 and mTORC2 variagate cytokine signaling to control NK maturation and effector function","volume":"9","author":"Wang","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.09.036_bib31","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/ni1325","article-title":"NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells","volume":"7","author":"Upshaw","year":"2006","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib32","doi-asserted-by":"crossref","first-page":"46081","DOI":"10.1074\/jbc.M308491200","article-title":"Crystal structure of the human natural killer (NK) cell activating receptor NKp46 reveals structural relationship to other leukocyte receptor complex immunoreceptors","volume":"278","author":"Foster","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.09.036_bib33","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/35642","article-title":"Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells","volume":"391","author":"Lanier","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.09.036_bib34","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","article-title":"Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.09.036_bib35","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1084\/jem.176.6.1751","article-title":"Fc gamma receptor activation induces the tyrosine phosphorylation of both phospholipase C (PLC)-gamma 1 and PLC-gamma 2 in natural killer cells","volume":"176","author":"Ting","year":"1992","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.09.036_bib36","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1084\/jem.169.2.549","article-title":"Fc gamma R(CD16) interaction with ligand induces Ca2+ mobilization and phosphoinositide turnover in human natural killer cells. Role of Ca2+ in Fc gamma R(CD16)-induced transcription and expression of lymphokine genes","volume":"169","author":"Cassatella","year":"1989","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.09.036_bib37","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.4049\/jimmunol.177.4.2349","article-title":"Vav1 controls DAP10-mediated natural cytotoxicity by regulating actin and microtubule dynamics","volume":"177","author":"Graham","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib38","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.285.5428.727","article-title":"Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA","volume":"285","author":"Bauer","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.09.036_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105459","article-title":"B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies","volume":"110","author":"Lee","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymthe.2026.09.036_bib40","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1084\/jem.20150792","article-title":"DNAM-1 controls NK cell activation via an ITT-like motif","volume":"212","author":"Zhang","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.09.036_bib41","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3389\/fimmu.2012.00377","article-title":"Evolving role of 2B4\/CD244 in T and NK cell responses during virus infection","volume":"3","author":"Waggoner","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib42","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.4049\/jimmunol.177.5.3170","article-title":"Molecular analysis of NTB-A signaling: a role for EAT-2 in NTB-A-mediated activation of human NK cells","volume":"177","author":"Eissmann","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib43","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/ni.1693","article-title":"Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function","volume":"10","author":"Cruz-Munoz","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib44","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.immuni.2012.03.023","article-title":"The adaptor SAP controls NK cell activation by regulating the enzymes Vav-1 and SHIP-1 and by enhancing conjugates with target cells","volume":"36","author":"Dong","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.09.036_bib45","doi-asserted-by":"crossref","first-page":"7996","DOI":"10.4049\/jimmunol.175.12.7996","article-title":"The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3K and phospholipase Cgamma signaling pathways in human NK cells","volume":"175","author":"Tassi","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.913215","article-title":"From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement","volume":"13","author":"Co\u00ebnon","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib47","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/342803a0","article-title":"Co-association of CD3 zeta with a receptor (CD16) for IgG Fc on human natural killer cells","volume":"342","author":"Lanier","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.09.036_bib48","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202009154","article-title":"PLCgamma1 promotes phase separation of T cell signaling components","volume":"220","author":"Zeng","year":"2021","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/jleuko\/qiac003","article-title":"The CD16 and CD32b Fc-gamma receptors regulate antibody-mediated responses in mouse natural killer cells","volume":"113","author":"Aguilar","year":"2023","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib50","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/jimmun\/vkaf012","article-title":"SYK negatively regulates ITAM-mediated human NK cell signaling and CD19-CAR NK cell efficacy","volume":"214","author":"Millan","year":"2025","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib51","doi-asserted-by":"crossref","first-page":"9611","DOI":"10.1073\/pnas.161298098","article-title":"Ubiquitination and degradation of Syk and ZAP-70 protein tyrosine kinases in human NK cells upon CD16 engagement","volume":"98","author":"Paolini","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.09.036_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1356666","article-title":"Therapeutic approaches to enhance natural killer cell cytotoxicity","volume":"15","author":"Stenger","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib53","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.it.2009.01.006","article-title":"NK cell education: not an on-off switch but a tunable rheostat","volume":"30","author":"Brodin","year":"2009","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib54","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1038\/s41467-019-13032-5","article-title":"Synergized regulation of NK cell education by NKG2A and specific Ly49 family members","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.09.036_bib55","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.it.2011.06.001","article-title":"Unifying concepts of MHC-dependent natural killer cell education","volume":"32","author":"Elliott","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084940","article-title":"Genetic diversity of the KIR\/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy","volume":"9","author":"De Re","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.09.036_bib57","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-17-1767","article-title":"Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group","volume":"24","author":"Erbe","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.09.036_bib58","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40425-019-0538-8","article-title":"Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab","volume":"7","author":"Erbe","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.09.036_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2022.152319","article-title":"The impact of killer cell immunoglobulin-like receptor (KIR) genes and human leukocyte antigen (HLA) class I ligands on predisposition or protection against prostate cancer","volume":"228","author":"Roshan Zamir","year":"2023","journal-title":"Immunobiology"},{"key":"10.1016\/j.ymthe.2026.09.036_bib60","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1399-0039.2011.01721.x","article-title":"KIR\/HLA gene combinations influence susceptibility to B-cell chronic lymphocytic leukemia and the clinical course of disease","volume":"78","author":"Karabon","year":"2011","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.ymthe.2026.09.036_bib61","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1399-0039.2009.01235.x","article-title":"Killer immunoglobulin-like receptors (KIR2DL2 and\/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia","volume":"73","author":"Middleton","year":"2009","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.ymthe.2026.09.036_bib62","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.bbmt.2009.06.015","article-title":"Donor KIR3DL1\/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation","volume":"15","author":"Gagne","year":"2009","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.ymthe.2026.09.036_bib63","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.humimm.2012.07.323","article-title":"KIR2DL2\/S2 and HLA-C C1C1 genotype is associated with better response to treatment and prolonged survival of patients with non-small cell lung cancer in a Polish Caucasian population","volume":"73","author":"Wi\u015bniewski","year":"2012","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib64","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.4049\/jimmunol.1200796","article-title":"Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses","volume":"189","author":"Hilpert","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib65","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1074-7613(00)80394-5","article-title":"Human diversity in killer cell inhibitory receptor genes","volume":"7","author":"Uhrberg","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.09.036_bib66","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nri1570","article-title":"MHC class I molecules and KIRs in human history, health and survival","volume":"5","author":"Parham","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib67","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1084\/jem.20091010","article-title":"KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A\u221711 while diminishing avidity for HLA-C","volume":"206","author":"Graef","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.09.036_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015115","article-title":"Different patterns of evolution in the centromeric and telomeric regions of group A and B haplotypes of the human killer cell Ig-like receptor locus","volume":"5","author":"Pyo","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.09.036_bib69","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2010-05-283051","article-title":"Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia","volume":"116","author":"Cooley","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.09.036_bib70","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood-2008-07-171926","article-title":"Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia","volume":"113","author":"Cooley","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.09.036_bib71","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nature03847","article-title":"Licensing of natural killer cells by host major histocompatibility complex class I molecules","volume":"436","author":"Kim","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.09.036_bib72","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.it.2017.12.001","article-title":"Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned","volume":"39","author":"Boudreau","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib73","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aag1672","article-title":"Class I HLA haplotypes form two schools that educate NK cells in different ways","volume":"1","author":"Horowitz","year":"2016","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib74","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00262-008-0601-7","article-title":"Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells","volume":"58","author":"Verheyden","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2026.09.036_bib75","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/imm.13439","article-title":"Activating receptor KIR2DS2 bound to HLA-C1 reveals the novel recognition features of activating receptor","volume":"165","author":"Yang","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2026.09.036_bib76","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3389\/fimmu.2012.00336","article-title":"Diverse functionality among human NK cell receptors for the C1 epitope of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3","volume":"3","author":"Moesta","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1033871","article-title":"Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy","volume":"13","author":"Zou","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib78","doi-asserted-by":"crossref","DOI":"10.1200\/OP-25-00675","article-title":"Re-Evaluating Donor Selection Priorities for Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide","author":"Mehta","year":"2026","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.ymthe.2026.09.036_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-70958-7","article-title":"Phase I study of safety and efficacy of allogeneic natural killer cell therapy in relapsed\/refractory neuroblastomas post autologous hematopoietic stem cell transplantation","volume":"14","author":"Mohseni","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2026.09.036_bib80","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-022-01382-5","article-title":"Natural killer cells in clinical development as non-engineered, engineered, and combination therapies","volume":"15","author":"Lamers-Kok","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib81","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/imr.12325","article-title":"Newtonian cell interactions shape natural killer cell education","volume":"267","author":"Goodridge","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2026.09.036_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1087155","article-title":"NK cell education: Physiological and pathological influences","volume":"14","author":"Rascle","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/cells14141091","article-title":"Natural Killer (NK) Cell Alloreactivity in Haploidentical Stem Cell Transplantation","volume":"14","author":"Luis-Hidalgo","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2026.09.036_bib84","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1182\/blood-2011-04-347070","article-title":"NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions","volume":"118","author":"Foley","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.09.036_bib85","doi-asserted-by":"crossref","first-page":"E4232","DOI":"10.1073\/pnas.1318255110","article-title":"Natural killer cell licensing in mice with inducible expression of MHC class I","volume":"110","author":"Ebihara","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.09.036_bib86","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201900434","article-title":"In vitro education of human natural killer cells by KIR3DL1","volume":"2","author":"Pugh","year":"2019","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.ymthe.2026.09.036_bib87","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.09.036_bib88","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00262-025-04196-9","article-title":"NKG2D CAR-NK adoptive cellular immunotherapy combined with or without PD-1 blockade in the treatment of patients with metastatic colorectal cancer: an exploratory study","volume":"74","author":"Wang","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2026.09.036_bib89","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood-2006-07-038687","article-title":"Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value","volume":"110","author":"Ruggeri","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.09.036_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005597","article-title":"Natural killer lysis receptor (NKLR)\/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells","volume":"4","author":"Markel","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.09.036_bib91","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.reth.2025.07.014","article-title":"Scalable production process development for NK cells targeting large-scale expansion","volume":"30","author":"Kikuchi","year":"2025","journal-title":"Regen. Ther."},{"key":"10.1016\/j.ymthe.2026.09.036_bib93","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s13402-025-01113-1","article-title":"Machine learning-based development of a cytotoxicity prediction model for NK cell therapy in cancers","volume":"48","author":"Ma","year":"2025","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.ymthe.2026.09.036_bib94","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2500319123","article-title":"A framework integrating multiscale in silico modeling and experimental data predicts CAR-NK cell cytotoxicity across target cell types","volume":"123","author":"Ahmad","year":"2026","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.09.036_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.110437","article-title":"Prediction of KIR3DL1 and human leukocyte antigen binding","author":"Maiers","year":"2025","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.09.036_bib96","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009560","article-title":"Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing","volume":"13","author":"Wang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.09.036_bib97","doi-asserted-by":"crossref","first-page":"8439","DOI":"10.1038\/s41467-024-52388-1","article-title":"CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells","volume":"15","author":"Bexte","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.09.036_bib98","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ymthe.2025.01.024","article-title":"Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells","volume":"33","author":"Shankar","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.09.036_bib99","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1158\/1078-0432.CCR-20-0575","article-title":"IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma","volume":"26","author":"Chauvin","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.09.036_bib100","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007502","article-title":"Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies","volume":"11","author":"Hasan","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.09.036_bib101","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","article-title":"Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity","volume":"27","author":"Zhu","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2026.09.036_bib102","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.2019000621","article-title":"Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity","volume":"135","author":"Zhu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.09.036_bib103","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1158\/2326-6066.CIR-19-0483","article-title":"Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells","volume":"8","author":"Ferrari de Andrade","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2026.09.036_bib104","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41590-025-02103-z","article-title":"Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFbeta and activin A suppression","volume":"26","author":"Rea","year":"2025","journal-title":"Nat. Immunol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626008063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626008063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:33:46Z","timestamp":1792438426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626008063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":103,"alternative-id":["S1525001626008063"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.09.036","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Receptor-ligand matching for precision allogeneic NK cell cancer therapies","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.09.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}